Healthcare analysts at sell-side firms FBR and Brean Capital were out today with some commentary on small-cap biotech companies Advaxis, Inc. (NASDAQ:ADXS) and Keryx Biopharmaceuticals (NASDAQ:KERX).
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that the Food and Drug Administration (FDA) has granted Fast Track …
Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, and Merck & Co.
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced their combination study with MedImmune, the global biologics research and development …
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) was halted at 8:15 Eastern Time and is now down 5% in pre-market trading after news that CEO Micheal …
(NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that data from a dose-escalation study of ADXS-HER2 in canine osteosarcoma (OSA) was …
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that it has entered into a co-development and commercialization agreement with …
Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced the appointment of Bradley J.
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, announced that it has added two more patents to its growing patent portfolio.
Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today its 2016 business outlook.
